Patent ID: 11883405
Assignee: AMPLIO PHARMA AB
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 14:
15. The pharmaceutical product according to claim 14, wherein the additional therapeutic agent is of one or more agents selected from the group consisting of non-steroidal anti-inflammatory agents (NSAIDs), glucocorticosteroids (GCSs), small molecule and/or biologic disease modifying agents (DMARDs), wherein the NSAIDs are selected from the group consisting of meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib, piroxicam, diclofenac, propionic acids, fenamates, pyrayoleones, and salicylates, wherein the GCSs, are selected from the group consisting of flunisolide, triamcinolone acetonide, betamethasone dipropionate, budesonide, fluticasone propionate, ciclesonide, and mometasone furoate, and wherein the DMARDs are selected from the group consisting of sulfasalazine, leflunomide, hydroxychloroquine, tofacitinib, d-penicillamine, infliximab, adalimumab, etanercept, abatacept, golimumab, anakinra, secukinumab, ixekizumab, rituximab, trastuzumab, certolizumab, tocilizumab, bordalumab, ustekinumab, and belimumab.